Pfizer and BioNTech announced that they are working on a Delta-specific vaccination
Pfizer and BioNTech announced that they were working on a Delta-specific vaccination to tackle the Covid form, which is highly transmissible. — Agence France-Presse.
Pfizer and BioNTech announced on Thursday that a third dose of their Covid-19 vaccine would be sought from the FDA.
According to a release, preliminary findings from a continuing experiment showed that a third shot increased antibody levels five to ten times against the original coronavirus strain and the Beta version, which was first discovered in South Africa, when compared to the first two doses alone.
According to the statement, “the businesses intend to publish more definitive data soon in a peer-reviewed publication and aim to submit the data to the FDA (Food and Drug Administration), EMA (European Medicines Agency), and other regulatory authorities in the coming weeks.”
Furthermore, the companies anticipate that a third dose will operate similarly well against the highly transmissible Delta strain, which is rapidly becoming the dominant strain worldwide.
Clinical trials are expected to begin in August, pending regulatory approval.
Based on efficacy drop-offs reported in Israel after six months, the firms anticipate a third dose may be required within six to 12 months.
To stay updated with the latest updates on celebrities, Hollywood, sports, technology and business, stay updated with the recent news of The Midget Herald.